Location History:
- Pittsburgh, PA (US) (2019)
- Hangzhou, CN (2020)
- Huzhou, CN (2022)
Company Filing History:
Years Active: 2019-2022
Title: Innovations of Zhanghui Chen in Cancer Treatment
Introduction
Zhanghui Chen is a prominent inventor based in Huzhou, China, known for his significant contributions to cancer treatment through innovative methods targeting fusion genes. With a total of 4 patents, his work focuses on advancing therapeutic techniques that can improve patient outcomes in oncology.
Latest Patents
Zhanghui Chen's latest patents include groundbreaking methods for treating cells containing fusion genes by genomic targeting. This invention relates to techniques for treating patients with cancer or premalignant conditions. It is based on the discovery that a genome editing technique specifically targeting a fusion gene can induce cell death in various cancer cells, such as hepatocellular cancer cells. The methods aim to produce an anti-cancer effect by performing genome editing techniques that target fusion genes present within the cells of a subject.
Another notable patent by Chen involves methods of treating cancers containing fusion genes. This invention is based on the discovery that the protein encoded by the MAN2A1-FER fusion gene exhibits kinase activity. The use of tyrosine kinase inhibitors targeting MAN2A1-FER in cancers other than prostate cancer, such as hepatocellular cancer, has shown dramatic improvements in survival rates for animals xenografted with the cancer.
Career Highlights
Zhanghui Chen is affiliated with the University of Pittsburgh, where he continues to conduct research and develop innovative cancer treatment methods. His work has garnered attention in the scientific community for its potential to change the landscape of cancer therapy.
Collaborations
Zhanghui Chen collaborates with esteemed colleagues, including Jianhua Luo and Yanping Yu, who contribute to his research efforts and innovations in the field of cancer treatment.
Conclusion
Zhanghui Chen's innovative approaches to treating cancer through genomic targeting of fusion genes represent a significant advancement in medical science. His contributions have the potential to improve the lives of many patients facing cancer diagnoses.